News brief­ing: PureTech plans Nas­daq de­but with sec­ondary list­ing; GoodRx prices $725M IPO

Lon­don Stock Ex­change-list­ed PureTech Health an­nounced Wednes­day that it’s look­ing to ex­tend to Nas­daq. But due to its “strong cash po­si­tion,” the biotech says it isn’t is­su­ing any new shares in the po­ten­tial sec­ondary list­ing.

The com­pa­ny’s shares closed at £256.50 Tues­day on the Lon­don Stock Ex­change. Its can­di­date LYT-100 is cur­rent­ly in Phase I de­vel­op­ment for var­i­ous in­di­ca­tions, in­clud­ing lym­phat­ic flow dis­or­ders and fi­brot­ic and in­flam­ma­to­ry dis­or­ders. PureTech is ex­pect­ing a Phase Ib read­out in lym­phat­ic flow dis­or­ders lat­er this year, and is al­so plan­ning to launch a Phase II study for the drug to treat res­pi­ra­to­ry con­di­tions ex­pe­ri­enced af­ter Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER